GlassScriptPhysician profile
Katlin Marie Thomas
NPI 1447940754
$363.24
in general payments reported to CMS, 2019-2025
15 companies · $133 in 2025
The $133 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $13.88 · 2024: $216 · 2025: $133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $363.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $363.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $81.19 | 2024 | Mounjaro, Zepbound |
| Vanda Pharmaceuticals INC. | $43.51 | 2025 | Fanapt |
| Corcept Therapeutics | $32.29 | 2025 | Korlym |
| Novo Nordisk INC | $21.86 | 2024 | Ozempic, Rybelsus |
| Hologic Sales and Service, LLC | $20.01 | 2025 | Aptima |
| Verona Pharma, INC. | $19.13 | 2025 | Ohtuvayre |
| Amgen INC. | $18.98 | 2024 | Repatha, Otezla |
| Shield Therapeutics INC | $18.37 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.18 | 2024 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $17.37 | 2024 | Voquezna |
| Glaxosmithkline, LLC. | $15.42 | 2024 | Trelegy Ellipta, Arexvy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.72 | 2024 | Caplyta |
| Astellas Pharma US INC | $14.27 | 2024 | Veozah |
| Mylan Specialty L.P. | $14.06 | 2024 | Yupelri |
| Exact Sciences Corporation | $13.88 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katlin Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.